ChengDa Pharmaceuticals Co., Ltd.

XSEC:301201 Stock Report

Market Cap: CN¥3.2b

ChengDa Pharmaceuticals Valuation

Is 301201 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301201 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301201 (CN¥21.26) is trading above our estimate of fair value (CN¥4.8)

Significantly Below Fair Value: 301201 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301201?

Key metric: As 301201 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 301201. This is calculated by dividing 301201's market cap by their current earnings.
What is 301201's PE Ratio?
PE Ratio45.9x
EarningsCN¥70.19m
Market CapCN¥3.22b

Price to Earnings Ratio vs Peers

How does 301201's PE Ratio compare to its peers?

The above table shows the PE ratio for 301201 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average54.8x
600613 Shanghai Shenqi Pharmaceutical Investment Management
72.8xn/aCN¥3.5b
000788 PKU HealthCareLtd
28.3xn/aCN¥3.6b
002688 Jinhe Biotechnology
34.1xn/aCN¥3.3b
002923 Zhuhai Rundu Pharmaceutical
83.8xn/aCN¥3.2b
301201 ChengDa Pharmaceuticals
45.9xn/aCN¥3.2b

Price-To-Earnings vs Peers: 301201 is good value based on its Price-To-Earnings Ratio (45.9x) compared to the peer average (54.8x).

Price to Earnings Ratio vs Industry

How does 301201's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
301201 45.9xIndustry Avg. 29.6xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 301201 is expensive based on its Price-To-Earnings Ratio (45.9x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 301201's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301201 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 301201's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

7D

-3.0%

1Y

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%